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Abstract
Eleven susceptibility loci for late-onset Alzheimer’s disease (LOAD) were identified by previous
studies; however, a large portion of the genetic risk for this disease remains unexplained. We
conducted a large, two-stage meta-analysis of genome-wide association studies (GWAS) in
individuals of European ancestry. In stage 1, we used genotyped and imputed data (7,055,881
SNPs) to perform meta-analysis on 4 previously published GWAS data sets consisting of 17,008
Alzheimer’s disease cases and 37,154 controls. In stage 2,11,632 SNPs were genotyped and tested
for association in an independent set of 8,572 Alzheimer’s disease cases and 11,312 controls. In
addition to the APOE locus (encoding apolipoprotein E), 19 loci reached genome-wide
significance (P < 5 × 10−8) in the combined stage 1 and stage 2 analysis, of which 11 are newly
associated with Alzheimer’s disease.
Alzheimer’s disease is a devastating neurological disorder primarily affecting the elderly.
The disease manifests with progressive deterioration in cognitive functions, leading to loss
of autonomy. The APOE gene (encoding apolipoprotein E) is a major genetic risk factor for
Alzheimer’s disease1,2. Previous GWAS in individuals of European ancestry identified nine
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other genomic regions associated with LOAD3–7. Recently, a rare susceptibility variant in
TREM2 was identified8,9. The search for additional genetic risk factors requires large-scale
meta-analysis of GWAS to increase statistical power. Under the banner of I-GAP
(International Genomics of Alzheimer’s Project), we conducted a meta-analysis of 4 GWAS
samples of European ancestry totaling 17,008 cases and 37,154 controls (stage 1) followed
up by genotyping of 11,632 SNPs showing moderate evidence of association (P < 1 × 10−3
in stage 1) in an independent sample that included 8,572 cases and 11,312 controls (stage 2).
In the stage 1 meta-analysis, we used data from four consortia: the Alzheimer’s Disease
Genetic Consortium (ADGC), the Cohorts for Heart and Aging Research in Genomic
Epidemiology (CHARGE) Consortium, the European Alzheimer’s Disease Initiative (EADI)
and the Genetic and Environmental Risk in Alzheimer’s Disease (GERAD) Consortium
(Table 1, Online Methods, Supplementary Table 1 and Supplementary Note). We used
European population reference (EUR) haplotype data from the 1000 Genomes Project (2010
interim release based on sequence data freeze from 4 August 2010 and phased haplotypes
from December 2010) to impute genotypes for up to 11,863,202 SNPs per data set. We
excluded SNPs that did not pass quality control in each study (Supplementary Table 2 and
Supplementary Note). Our meta-analysis included SNPs either genotyped or successfully
imputed in at least 40% of the Alzheimer’s disease cases and 40% of the control samples
across all data sets (7,055,881 SNPs; Online Methods). In each data set, genotype dosages
were analyzed as described in the Supplementary Note (Supplementary Table 2). We
performed meta-analysis of the results after applying genomic control correction to each
study. The genomic control inflation factor for the meta-analysis was 1.087 for the full set of
SNPs and 1.082 after excluding SNPs within the APOE locus (chr. 19: 45,409,039–
45,412,650) and within 500 kb of SNPs associated with Alzheimer’s disease at a
prespecified level of genome-wide significance (P < 5 × 10−8) in stage 1 (see Supplementary
Fig. 1 for quantile-quantile plots).
In addition to the APOE locus, 14 genomic regions had associations that reached the
genome-wide significance level (Fig. 1). Nine had been previously identified by GWAS as
genetic susceptibility factors3–7, and five (HLA-DRB5–HLA-DRB1, PTK2B, SORL1,
SLC24A4-RIN3 and DSG2) represent newly associated loci (Table 2). SORL1 had
previously been identified as an Alzheimer’s disease gene through candidate gene
approaches and in a GWAS combining ADGC and Asian samples10. Genes attributed to a
signal were those closest to the most significantly associated SNP. However, we are aware
that these are potentially not the causative genes. Detailed results for each region are given
in Supplementary Figure 2–7.
In stage 2, we selected for genotyping all stage 1 SNPs with a P value less than 1 × 10−3,
excluding SNPs flanking APOE (chr. 19: 45,409,039–45,412,650) (n = 19,532; see URLs
for database access). From the initial set of SNPs, 14,445 could be genotyped using Illumina
iSelect technology. After quality control procedures (Online Methods), we considered
11,632 SNPs for association analysis. The stage 2 sample included 8,572 cases and 11,312
controls of European ancestry originating from Austria, Belgium, Finland, Germany,
Greece, Hungary, Italy, Spain, Sweden, the UK and the United States (Table 1 and
Supplementary Note). We observed 116 SNPs showing the same risk allele and direction of
association in stages 1 and 2 that were significantly associated with Alzheimer’s disease risk
in stage 2 after a strict Bonferroni correction for multiple testing (P < 4.3 × 10−6). Of these
116 SNPs, 80 had been associated at genome-wide significance with Alzheimer’s disease
risk in stage 1. Additionally, in analyses in stage 2, 2,562 SNPs were associated with
Alzheimer’s disease at a nominal level of significance (P < 0.05), having the same risk allele
and direction of association as in stage 1.
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The results from stages 1 and 2 and from the combined stage 1 and stage 2 data sets, which
represent a secondary discovery effort, are shown in Table 2. With the exception of CD33
and DSG2, we nominally replicated all loci that surpassed the genome-wide significance
level in stage 1. Inability to replicate DSG2 is not surprising, as evidence of association for
this locus was based on data for a single SNP and was not supported by data from
surrounding SNPs in linkage disequilibrium (LD, r2 > 0.8; Supplementary Fig. 7b).
Moreover, seven new loci reached the genome-wide significance level in the combined
analysis (Table 2). More detailed results for the seven newly identified LOAD loci are
provided in Supplementary Figure 8–11. There was no significant heterogeneity across
studies at any of the loci, except at DSG2 (Table 2 and Supplementary Fig. 12–16). To
identify potential causative genes, we also examined all SNPs with association P < 5× 10−8
that were within 500 kb of the top SNP at each locus to identify cis expression quantitative
trait locus (cis-eQTL) associations (Online Methods and Supplementary Table 3).
The results from the combined stage 1 and stage 2 data sets also identified 13 loci with
suggestive evidence of association (P < 1 × 10−6) (Supplementary Table 4). Among these,
we detected a signal for rs9381040 (P = 6.3 × 10−7), which is located approximately 5.5 kb
away from the 3′ end of TREML2 and 24 kb away from the 5′ end of TREM2. TREM2 was
recently reported to carry a rare variant (encoding p.Arg47His) associated with three- to
fourfold increased risk of developing Alzheimer’s disease8,9. This region also reached
genome-wide significance in a study of cerebral spinal fluid levels of phosphorylated tau, a
biomarker for Alzheimer’s disease11.
Beyond the already known, GWAS-defined genes (ABCA7, BIN1, CD33, CLU, CR1,
CD2AP, EPHA1, MS4A6A–MS4A4E and PICALM), the most significant new association
was in the HLA-DRB5–DRB1 region (encoding major histocompatibility complex, class II,
DRβ5 and DRβ1, respectively). This region is associated with immunocompetence and
histocompatibility and, interestingly, with risk of both multiple sclerosis and Parkinson
disease12,13. Owing to the complex genetic organization of the human leukocyte antigen
(HLA) region on chromosome 6, we were unable to define which gene(s) are responsible for
this signal (Supplementary Fig. 6a).
The second strongest signal was within the SORL1 gene (encoding sortilin-related receptor,
L(DLR class) 1). Our data clearly demonstrated that this gene was associated at genome-
wide significance in European samples. SORL1 is noteworthy, as it is associated with
increased risk of both autosomal dominant and sporadic forms of Alzheimer’s disease14,15
and represents the first LOAD gene that directly connects aberrant trafficking and
metabolism of the amyloid precursor protein (APP) to LOAD14.
The third locus, PTK2B (encoding protein tyrosine kinase 2β), is only approximately 130 kb
away from CLU, but we believe the two signals are independent because (i) the two most
strongly associated SNPs within each of these two genes are not in LD (D′ = 0.06 and r2 =
0.003 as computed using 1000 Genomes Project data); (ii) a recombination peak exists
between the two loci (Fig. 2); and (iii) conditional analysis in the stage 2 data confirmed the
independence of the PTK2B association (Supplementary Fig. 17 and Supplementary Table
5). The protein encoded by PTK2B may be an intermediate between neuropeptide-activated
receptors or neurotransmitters that increase calcium flux and the downstream signals
regulating neuronal activity such as mitogen-activated protein kinase (MAPK) signaling16.
PTK2B is involved in the induction of long-term potentiation in the hippocampal CA1
(cornu ammonis 1) region, a central process in the formation of memory17. We cannot,
however, exclude the possibility that there are multiple signals in the PTK2B–CLU region
that are functionally connected to a single gene. For instance, two SNPs associated with
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genome-wide significance in the PTK2B–CLU region are eQTLs for the gene DPYSL2 that
has been implicated in Alzheimer’s disease18 (Supplementary Table 3).
The fourth locus was SLC24A4 (encoding solute carrier family 24 (sodium/potassium/
calcium exchanger), member 4). The SLC24A4 gene encodes a protein involved in iris
development and hair and skin color variation in humans in addition to being associated
with the risk of developing hypertension19,20. SLC24A4 is also expressed in the brain and
may be involved in neural development21. Of note, in the vicinity of the most strongly
associated SNP is another gene called RIN3 (encoding Ras and Rab interactor 3), and its
gene product directly interacts with the BIN1 gene product22, a protein that may be
connected to tau-mediated pathology23.
In addition to these four loci reaching genome-wide significance in stage 1, seven new loci
reached genome-wide significance in the combined analysis.
The strongest association at one of these new loci was intronic in the ZCWPW1 gene
(encoding zinc finger, CW type with PWWP domain 1), whose corresponding protein
modulates epigenetic regulation24. However, the region defined by all the SNPs associated
with Alzheimer’s disease risk in our data is large and contains about ten genes
(Supplementary Fig. 9b). Another interesting possible candidate gene in the ZCWPW1
region is NYAP1, as disruption of the corresponding gene in mice affects brain size, neurite
elongation and, more generally, neuronal morphogenesis25. Our data do not resolve which
gene in this region may be causal.
A second locus was within the CELF1 gene (encoding CUGBP, Elav-like family member
1), whose gene product is a member of the protein family that regulates pre-mRNA
alternative splicing26. As with the ZCWPW1 locus, the region of interest is large and
contains about ten genes (Supplementary Fig. 10a). Among these genes is MADD (encoding
MAP kinase–activating death domain), the reduced expression of which may affect long-
term neuronal viability in Alzheimer’s disease27.
A discrete signal was observed adjacent to NME8 (encoding NME/ NM23 family member
8), which is responsible for primary ciliary dyskinesia type 6 (ref. 28).
The FERMT2 gene (encoding fermitin family member 2) is expressed in the brain. Its
corresponding protein localizes to cell matrix adhesion structures, activates integrins, is
involved in the orchestration of actin assembly and cell shape modulation, and is an
important mediator of angiogenesis29. An association between the Drosophila melanogaster
ortholog of FERMT2 (fit1/fit2) and tau-mediated toxicity was recently described30.
We identified a fifth signal on chromosome 20 at CASS4 (encoding Cas scaffolding protein
family member 4). Little is known about the function of the encoded protein. However, the
Drosophila CASS family ortholog (p130CAS) binds to CMS, the Drosophila ortholog of
CD2AP (CMS), a known Alzheimer’s disease susceptibility gene (Table 2) that is involved
in actin dynamics31.
Another locus was identified at INPP5D (encoding inositol polyphosphate-5-phosphatase,
145 kDa) on chromosome 2. INPP5D is expressed at low levels in the brain, but the encoded
protein has been shown to interact with CD2AP, whose corresponding gene is one of the
Alzheimer’s disease genes previously identified by GWAS32, and to modulate, along with
GRB2, metabolism of APP33.
We identified a seventh signal adjacent to MEF2C (encoding myocyte enhancer factor 2).
Mutations at this locus are associated with severe mental retardation, stereotypic
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movements, epilepsy and cerebral malformation34. The MEF2C protein limits excessive
synapse formation during activity-dependent refinement of synaptic connectivity and thus
may facilitate hippocampal-dependent learning and memory35.
In summary, our Alzheimer’s disease GWAS meta-analysis has identified 11 new
susceptibility loci in addition to the already known ABCA7, APOE, BIN1, CLU, CR1,
CD2AP, EPHA1, MS4A6A–MS4A4E and PICALM genes. However, we were not able to
replicate association of CD33 in our stage 2 analysis (P = 0.61). We did not detect any
biases in terms of imputation in our discovery data sets or genotyping in our replication data
sets (data not shown), suggesting a potential statistical fluctuation across our populations as
an explanation for the lack of replication. However, recent data suggest that genetically
determined decreased CD33 expression might reduce Alzheimer’s disease risk and interfere
with amyloid β peptide clearance36, a dysfunction thought to be central in late-onset forms
of Alzheimer’s disease37. Further investigations in independent case-control studies will
thus be required to confirm or refute the association of CD33 with Alzheimer’s disease.
The newly associated loci reinforce the importance of some previously suspected pathways
such as APP (SORL1 and CASS4) and tau (CASS4 and FERMT2) in pathology. Several
candidate genes at these loci are involved in pathways already shown to be enriched for
association signal in Alzheimer’s disease GWAS38,39, such as immune response and
inflammation (HLA-DRB5–DRB1, INPP5D and MEF2C), which is also supported by the
described association of Alzheimer’s disease with CR1 (ref. 3) and TREM2 (refs. 8,9), cell
migration (PTK2B) and lipid transport and endocytosis (SORL1). Our results also suggest
the existence of new pathways underlying Alzheimer’s disease. These pathways could
include hippocampal synaptic function (MEF2C and PTK2B), cytoskeletal function and
axonal transport (CELF1, NME8 and CASS4), regulation of gene expression and post-
translational modification of proteins, and microglial and myeloid cell function (INPP5D).
Examining the genetic effect attributable to all the associated loci, we demonstrated that the
most strongly associated SNPs at each locus other than APOE had population-attributable
fractions (PAFs) or preventive fractions between 1.0–8.0% in the stage 2 sample
(Supplementary Table 6). Strong efforts in sequencing and post-GWAS analyses will now
be required to fully characterize the candidate genes and functional variants responsible for
the association of these GWAS-identified loci with Alzheimer’s disease risk and to
understand their exact roles in the pathophysiology of Alzheimer’s disease40,41.
URLs. Database access, http://www.pasteur-lille.fr/en/recherche/u744/Igap_stage1.zip;
IMPUTE2, http://mathgen.stats.ox.ac.uk/impute/impute_v2.html; MaCH, http://
www.sph.umich.edu/csg/abecasis/MACH/; ProbABEL, http://www.genabel.org/packages/
ProbABEL; SMARTPCA, http://www.hsph.harvard.edu/alkes-price/software/; GWAMA,
http://www.well.ox.ac.uk/gwama/; LocusZoom, http://csg.sph.umich.edu/locuszoom/;
PLINK, http://pngu.mgh.harvard.edu/~purcell/plink/; SNPTEST, https://
mathgen.stats.ox.ac.uk/genetics_software/snptest/snptest.html; Aberrant, http://
www.well.ox.ac.uk/software; Metal, http://www.sph.umich.edu/csg/abecasis/metal/; R,
http://www.r-project.org/; R meta, http://cran.r-project.org/web/packages/rmeta/index.html;
eQTL analyses (accessed 18 February 2013), http://eqtl.uchicago.edu/cgi-bin/gbrowse/eqtl.
ONLINE METHODS
All case-control studies are described in Table 1, in the Supplementary Note (see full
description of the I-GAP data sets) and in Supplementary Tables 1, 7 and 8. Written
informed consent was obtained from study participants or, for those with substantial
cognitive impairment, from a caregiver, legal guardian or other proxy, and the study
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protocols for all populations were reviewed and approved by the appropriate institutional
review boards.
Imputation and SNP selection for stage 1 analysis
After quality control criteria were finalized for each individual and each sample collection
(SNPs with call rates of <95% were excluded; Supplementary Note), IMPUTE2 (ref. 42) or
MaCH/Minimac43 software (Supplementary Table 2) was used to impute the genotypes of
all participants with haplotypes derived from samples of European ancestry in the 1000
Genome Project (2010 interim release based on the sequence data freeze from 4 August
2010 and phased haplotypes from December 2010). In each data set, SNPs with R2 or info
score quality estimates of less than 0.3, as indicated by MaCH or IMPUTE2, respectively
(with these two quality estimates described to be equivalent), were excluded from analyses.
Similarly, SNPs with a MAF of <1% were also excluded. After these procedures, a
maximum of 8,133,148 SNPs were retained that were present in at least 1 data set.
In each case-control data set, the association of LOAD with genotype dosage was analyzed
by a logistic regression model including covariates for age, sex and principal components to
adjust for possible population stratification (Supplementary Table 2). For the three
CHARGE cohorts with incident Alzheimer’s disease data, Cox proportional hazards models
were used. The four consortia used different but analogous software for these analyses
(PLINK44, SNPTEST45, ProbABEL46 or R; Supplementary Table 2). Three of these tools
were applied to the EADI data set for quality control, and very similar results were
observed. After the exclusion of SNPs showing logistic regression coefficient |β| > 5 or P
value equal to 0 or 1, the maximum number of SNPs in any data set was 8,131,643. Each
consortium uploaded summarized results for each SNP to an internal I-GAP website for
access by members of each consortium.
SNPs genotyped or imputed in at least 40% of Alzheimer’s disease cases and 40% of control
samples were included in the meta-analysis. This threshold represented the best compromise
between maximizing the total number of SNPs and maximizing the number of samples in
which the given SNP was present. Indeed, analyzing all SNPs available in at least one study
could have greatly increased the risk of false positives. On the other hand, studying SNPs
only present in all studies could have led to the removal of SNPs of potential interest, even if
those SNPs could have reached adequate statistical power in a more limited number of data
sets (false negatives). This approach allowed us to increase homogeneity between studies for
some SNPs by excluding poor quality data present only in a limited number of data sets of
small size. This last selection step led to a final number of 7,055,881 SNPs in stage 1
analysis.
iSelect microarray design and stage 2 SNP quality control
SNPs associated with Alzheimer’s disease risk and exhibiting P value < 1 × 10−3 in stage 1
analysis were selected for replication. A list of 19,532 SNPs was submitted to a devoted
Illumina website to develop an iSelect microarray. A total of 16,732 SNPs exhibiting an
Illumina score superior or equal to 0.4 were selected for microarray production. During the
Illumina production process, 2,287 SNPs failed oligonucleotide synthesis, leading to a final
number of 14,445 SNPs for which genotyping was attempted. Genotyping failure led to the
further exclusion of an additional 1,999 SNPs as a result of the SNPs (i) having no intensity
signal (n = 559), (ii) not being polymorphic (n = 1,176), (iii) only being found in a
heterozygous state (n = 248) or (iv) having mismatched alleles compared to 1000 Genomes
Project data (n = 16). Finally, several quality control measures were applied to the remaining
12,446 SNPs to detect potential biases in genotyping. We first tested for discrepancies in
allelic frequency between the 1000 Genomes Project EUR reference panel and stage 2 data.
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Allele frequencies for stage 2 data were estimated on 10,750 controls (see “Stage 2 sample
quality control”) and after exclusion of Finnish individuals. The allelic test was performed
with PLINK, and P values were computed by performing 4,500,000 permutations to avoid
an assumption of Hardy-Weinberg equilibrium. In total, 798 SNPs showed a highly
significant difference in terms of allele frequency between the 1000 Genomes Project EUR
reference panel and stage 2 data (P < 1 × 10−5; Supplementary Fig. 18) and were excluded
from the analysis.
Other SNP quality control steps were performed separately in data for each country. A SNP
was considered of low genotyping quality in a country data set if it had missing genotype
data for more than 10% of the individuals, if the P value for the Hardy-Weinberg test in
controls was lower than 1 × 10−6 or if the P value for the test for differences in missingness
between cases and controls was lower than 1 × 10−6 (see Supplementary Table 9 for
differences in missingness assessed for suggestive and significant hits across European
populations). These quality control steps led to the removal of 16 SNPs with low genotyping
quality in data from all countries.
After SNP quality control, 11,632 SNPs were considered to be of high genotyping quality in
at least 1 country and were analyzed in stage 2. For imputed data sets, SNPs were
considered to be of low imputation quality if their info score was <0.3.
Of note, of the 7,086 SNPs that we were unable to successfully genotype, only 471 were not
tagged by another successfully genotyped variant (±100 kb) and associated with a P value at
least 10 times higher than that of the missing SNP. Because the vast majority of the
untagged SNPs exhibited stage 1 P values between 1 × 10−3 and 1 × 10−4 (92%), the
likelihood of missing a true association was considered to be low.
Stage 2 sample quality control
The iSelect microarray contained 33,368 SNPs, of which 11,632 were devoted to stage 2.
These supplementary SNPs included various genetic data that allowed us to further refine
our quality control processes. On the basis of data for all of these SNPs, we excluded
individuals who had more than 3% missing genotypes, showed a discrepancy between
reported sex and sex estimated on the basis of genetic data (genetic sex) or showed evidence
of non-European ancestry. Duplicated and related individuals were identified
(Supplementary Table 10). Briefly, discrepancies in sex were examined using genetic sex as
estimated by PLINK on 40 SNPs on chromosome X. We also removed 93 individuals from
a single plate for whom an abnormal number of discrepancies in sex were observed,
suggesting that sample mixing had occurred. Using a panel of 261 ancestry-informative
markers (AIMs), we performed a principal-component analysis (PCA) on HapMap 2 data
with the function SMARTPCA from EIGENSOFT 4.2 software47. For each country,
individuals were projected onto the first two PCA axes to define their genetic ancestry.
Individuals with evidence of non-European ancestry were then identified by applying a
Bayesian clustering approach48 to their coordinates on the first two axes. Identity by descent
(IBD) was computed for all pairs of individuals using PLINK, and individuals in a pair with
IBD greater than 0.98 were considered to be duplicates. If clinical data for duplicated
individuals were discordant, both individuals were excluded. Otherwise, the individual with
the greater proportion of missing genotype was excluded. Similarly, IBD was computed for
all pairs of individuals in data from each country separately, using 6,764 autosomal SNPs
with MAF of >1% and selected to minimize LD. Individuals in pairs with IBD greater than
0.2 were considered to be related and were iteratively removed so as to obtain a sample of
unrelated individuals within each country data set.
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Finally, individuals with missing clinical data and controls less than 25 years of age were
excluded from the analysis. After sample quality control (Supplementary Table 10), 19,884
individuals (8,572 cases and 11,312 controls) were available for analysis in stage 2.
Statistical analysis
For the stage 1 meta-analysis, we undertook fixed-effects inverse variance-weighted meta-
analysis with the standard errors of the β-coefficient scaled by the square roots of study-
specific genomic inflation factors estimated before combining the summary statistics across
data sets. Each consortium performed an independent stage 1 meta-analysis after
downloading the data files available on the I-GAP website. Two software packages were
used for meta-analysis: METAL49 and GWAMA50. Very similar results were generated
independently of the software used and as expected, perfect matching was observed between
the analyses undertaken by each of the 4 consortia.
For stage 2, association tests were performed for each country for all high-quality genotyped
SNPs under an additive model, using logistic regression as implemented in PLINK. Analysis
was adjusted for age, sex and principal components, when necessary. Using SMARTPCA,
PCA was performed on individuals from each country separately. Difference in PCA
coordinates between cases and controls were tested for the first four principal components,
and analysis was further adjusted on principal components if the P value of this test was
lower than 0.05. PCA for Bonn stage 2 samples was based on GWAS data. For imputed data
sets, association tests were performed using likelihood score tests for missing data as
implemented in SNPTEST. Genotyped and imputed German samples were analyzed
separately, and results were then combined by fixed-effects meta-analysis using the inverse
variance approach as implemented in METAL. Using this approach, a fixed-effects meta-
analysis was then performed to combine stage 2 results from the different countries. We also
performed the analysis separately for each center in stage 2 and combined the results by
fixed-effects meta-analysis. Results were similar to those obtained when analysis was
performed by country (data not shown).
We finally generated fixed-effects inverse variance–weighted meta-analyses by combining
summary statistics across ADGC, CHARGE, EADI, GERAD and stage 2 data by country.
At this point, we performed Cochran’s Q test for heterogeneity and generated I2 estimates
with METAL to evaluate the possible effect of study heterogeneity on the results.
A graphic representation of the association signal in the stage 1 data was generated with
LocusZoom software51 for all the loci of interest reaching a genome-wide significant level
after combined stage 1 and stage 2 analyses.
PAF was calculated using the Levin equation52.
Annotation of I-GAP top SNPs for eQTLs
To gain further biological insights, we explored reported associations between SNPs in the
top I-GAP loci and gene expression. We first selected all SNPs that reached genome-wide
significance (P value ≤ 5 × 10−8) in the combined stage 1 and stage 2 analysis and were
located in a 500-kb window upstream or downstream of the top SNP at each locus (Table 2).
We then searched for published data on gene expression associated with each of these SNPs
in the eQTL database from the Pritchard laboratory (see URLs). For each reported eQTL
gene and each type of eQTL association as defined in this database, we then counted the
number of reported eQTL SNPs and selected the one with the lowest P value.
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Manhattan plot of stage 1 for genome-wide association with Alzheimer’s disease (17,008
cases and 37,154 controls). The threshold for genome-wide significance (P < 5 × 10−8) is
indicated by the red line. Genes previously identified by GWAS are shown in black, and
newly associated genes are shown in red. Red diamonds represent SNPs with the smallest P
values in the overall analysis.
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Regional plot for the PTK2B-CLU locus (17,008 cases and 37,154 controls).
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Table 1
Description of the consortium data sets used for stage 1 and stage 2











ADGC 10,273 59.4 74.7 (7.7) 10,892 58.6 76.3 (8.1)
CHARGE 1,315 63.6 82.7 (6.8) 12,968 57.8 72.8 (8.6)
EADI 2,243 64.9 68.5 (8.9) 6,017 60.7 74.0 (5.4)












Austria 210 61.0 72.5 (8.1) 829 43.3 65.5 (8.0)
Belgium 878 66.1 75.4 (8.6) 661 59.5 65.7 (14.3)
Finland 422 68.0 71.4 (6.9) 562 59.3 69.1 (6.2)
Germany 972 63.9 73.0 (8.6) 2,378 53.1 69.5 (10.1)
Greece 256 63.3 69.2 (8.0) 229 34.1 49.3 (16.4)
Hungary 125 68.0 74.9 (6.8) 100 69.0 74.4 (6.5)
Italy 1,729 66.5 71.5 (8.7) 720 55.7 70.0 (10.4)
Spain 2,121 66.3 75.0 (8.3) 1,921 55.3 70.2 (10.8)
Sweden 797 61.7 76.8 (8.1) 1,506 62.8 70.6 (8.7)
UK 490 57.6 74.6 (8.7) 1,066 29.2 73.8 (6.5)
United States 572 61.9 83.5 (7.6) 1,340 54.0 79.3 (6.8)
N 8,572 11,312
AAO, age at onset; AAE, age at examination.
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